Skip to main content

LIPOSKILL is a simple and natural procedure that does not rely on the injection of artificial components into the skin

LIPOSKILL Advantages

No artificial components: this is the first among the advantages of LIPOSKILL treatments, which do not require the use of foreign substances or materials.

The primary difference between our facial treatments and artificial treatments (such as Botox) is that LIPOSKILL rely only on the injection of your cells. Autologous adipose-derived stem cells (ADSCs) restore the youthful contour and shape of your face, performing, if needed, a dual action: increasing the volume, and renewing the skin. Treatments such as Botox can reduce the effect of wrinkles, but they cannot give again youth to your skin. Botox will smooth out your wrinkles, but will leave you with “old-looking” skin: that is why we recommended LIPOSKILL even before a Botox treatment.

In body shaping treatments, LIPOSKILL offers another dual aesthetic advantage: reducing fat volume in a specific area (e.g. abdomen or thigh) and, at the same time, increasing the volume of a different area of the body, such as breasts or buttocks. Also, LIPOSKILL can be used to correct asymmetries or damages caused by previous plastic surgeries or injuries.

Adipose-derived stem cells-based treatments represent the new frontier in Regenerative Medicine. Several recent investigations pave the way to their successful therapeutic application in tissue repair.

The Regenerative Capacity of Adipose Derived Stem Cells (ADSCs)

Stem cells opened an unprecedented hope for the treatment (and perhaps the recovery) of severely damaged tissues that cannot be rescued by the most advanced pharmacological and surgical treatments. This outlook paved the way to a new approach to complex diseases management, the so called Regenerative Medicine, that could heal chronic diseases and help a healthy and active aging, with exceptional socioeconomic implications.(1)

1. Regenerative Capacity of Adipose Derived Stem Cells (ADSCs), Comparison with Mesenchymal Stem Cells (MSCs) – Loubna Mazini, Luc Rochette, Mohamed Amine and Gabriel Malka – doi: 10.3390/ijms20102523